Frequency Therapeutics Begins Clinical Trials for Hearing Loss Drug
C2I alumni, Frequency Therapeutics, has begun to treat patients in Phase I/II clinical trials to determine the efficacy of their drug for restoring hearing. The clinical trial includes 24 patients with stable sensorineural hearing loss and will receive an injection of drug candidate FX-322 or a placebo in their ear along with a follow-up visit after two weeks. After the follow-up, Frequency will monitor the patients for another three months.
Congratulations Frequency Therapeutics!
Read the full article here.